MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost

MannKind received FDA approval for Furoscix ReadyFlow on Friday.

The approval was accompanied by a $50 million funding boost.

MNKD stock rose 8% following the news.

Furoscix ReadyFlow is a product for heart failure treatment.